Market closed

Regeneron/$REGN

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Regeneron

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Ticker

$REGN
Trading on

Industry

Biotechnology

Employees

14,165

Regeneron Metrics

BasicAdvanced
$76B
Market cap
17.52
P/E ratio
$40.43
EPS
0.14
Beta
-
Dividend rate
$76B
0.14
$1,206.81
$693.00
861K
5.281
4.344
9.221
9.221
65.53%
7.27%
17.17%
17.519
5.504
2.6
2.71
22.959
5.72%
15.31%
0.74%
-13.53%

What the Analysts think about Regeneron

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Regeneron stock.

Regeneron Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Regeneron Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $REGN

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Regeneron stock?

Regeneron (REGN) has a market cap of $76B as of December 21, 2024.

What is the P/E ratio for Regeneron stock?

The price to earnings (P/E) ratio for Regeneron (REGN) stock is 17.52 as of December 21, 2024.

Does Regeneron stock pay dividends?

No, Regeneron (REGN) stock does not pay dividends to its shareholders as of December 21, 2024.

When is the next Regeneron dividend payment date?

Regeneron (REGN) stock does not pay dividends to its shareholders.

What is the beta indicator for Regeneron?

Regeneron (REGN) has a beta rating of 0.14. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.